Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Diego Escobar

Undersea and Hyperbaric Medicine New Rochelle, NY Medical Doctor

NPI 1881622181 CMS profile 502406

355 Pelham Rd, New Rochelle, NY 10805

Open in the dashboard

General payments

$3,314

90 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diego Escobar of New Rochelle, NY is reported in the CMS Open Payments database as having received $3,314 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,556 39
2024 General $1,512 40
2023 General $246 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diego Escobar
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Diego Escobar were reported at $1,556. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.

Show as a table
Year Diego Escobar Undersea and Hyperbaric Medicine median Middle half National median
2019 $0 $201 $85–$538 $163
2020 $0 $84 $31–$222 $114
2021 $0 $138 $52–$383 $132
2022 $0 $135 $51–$385 $149
2023 $246 $143 $75–$442 $160
2024 $1,512 $178 $80–$442 $164
2025 $1,556 $208 $52–$518 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Smith+Nephew, Inc. $1,527 27 payments
  2. ETS Wound Care LLC $575 16 payments
  3. Organogenesis Inc. $490 20 payments
  4. Cashflow Solutions, LLC $178 2 payments
  5. Kerecis Limited $126 6 payments
  6. Hydrofera LLC $115 3 payments
  7. Solventum Corporation $95 4 payments
  8. MIMEDX Group, Inc. $93 6 payments
  9. Urgo Medical North America, LLC $56 3 payments
  10. Integra LifeSciences Corporation $45 2 payments
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,314 90 payments
Products named General payments · program years 2023–2025
  1. GRAFIX PL Other Advanced Wound Management $745 7 payments
  2. GRAFIX PL Other Advanced Wound Management $552 7 payments
  3. MIRRAGEN ADVANCED WOUND MATRIX $503 14 payments
  4. Lympha Press Optimal Plus(US) BT $178 2 payments
  5. PCD-51 731A (US) - White $178 2 payments
  6. PCD-52 737A (US) White $178 2 payments
  7. APLIGRAF $176 5 payments
  8. COLLAGENASE SANTYL $155 9 payments
  9. NuShield $124 2 payments
  10. HYDROFERA BLUE $82 2 payments
  11. Other $1,071 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

136

Prescriptions dispensed, refills included

Drug cost

$9,729

Paid at the pharmacy, in all

Branded share of claims

29.4%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 16 $8,372
Gentamicin Sulfate Generic 17 $643
Ciprofloxacin Hcl Generic 38 $212
Nystatin Generic 13 $186
Doxycycline Hyclate Generic 28 $158
Acetaminophen-Codeine Acetaminophen With Codeine Brand 11 $128
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$88,358

Medicare's payments for the services billed

Medicare patients

113

Average age 76

Services billed

1,224

53 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Ischemic heart disease 51%
Diabetes 50%
Chronic kidney disease 43%
Heart failure 38%
Depression 34%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record